India: In Quest for Next Gen Pharma Profession?als
The Indian pharmaceutical sector, driven by increased knowledge skills, improved quality and increased demand (domestic and international), has witnessed tremendous growth during the past few years. India is among the top six producers of pharmaceuticals in the world and ranks fourth in terms of total pharma market share in the Asia Pacific.1 The country requires a large pool of skilled manpower to meet the growing demands of the growing Indian pharmaceutical industry.
The origin of pharmacy education in India dates back to 1899 in Madras where the first pharmacy institution was set up.2 In the year 1932, Prof M LSchroff, father of pharmacy education in India, started the undergraduate programme in pharmacy at Banaras Hindu University, which soon witnessed a rise in pharmacy schools around the country.3
Pharmacy education developed at a much faster rate in India since the late 1980s spurred by rapid growth, privatisation and economic growth in the sector. At present there are more than 1500 institutions offering various pharmacy programmes at undergraduate, post graduate, diploma and Pharm. D level with a combined annual intake of more than 100,000 students.4
“The availability of vast pool of technically skilled manpower and well-established state of art research units has made Indian pharma as global pharma destination for R&D activities. With successful implementation of post graduate programmes in hospital setting and research institutions, the ecosystem is encouraging the private sector to engage in R&D and develop innovative products,” said Mr Rajeev Kher, Additional Secretary, Department of Commerce, Ministry of Commerce and Industry, Government of India.
The domestic pharma market is estimated to touch US$49 billion by 2020.5 The projected human resource requirement to match this growth is estimated to be about 21,50,000 by 2020.6 The Government of India has taken a series of measures to meet the projected demand of pharma professionals in the future:
1. The Department of Pharmaceuticals has projected an investment Rs 3000 crore (US$ 478.4 million) to set up 10 more National Institute of Pharmaceutical Education and Research (NIPER) over the next few years to strengthen the human resource base.7
2. Clinical Research Education and Management Academy (CREMA) is another institute that exclusively provides courses specific to clinical research and healthcare management. It is amongst the first institutions dedicated to promoting high-quality clinical research and healthcare management education.
3. Scholarships programmes are awarded to the meritorious students, which help inculcate a competitive spirit amongst students pursuing higher education. Some noteworthy examples include:
• Central Sector Scheme of Scholarship for College and University Students
• Post Graduate Scholarship for All India Council for Technical Education
• AICTE, UGC and NIPER provide merit based stipend and fellowship grants to students pursuing higher education in pharmacy
4. The introduction of Pharm D programme along with the revised framework of Indian pharmacy education is expected to ensure quality human resources meeting global standards.
“Healthcare is changing more rapidly than almost any other field. Demand drivers like increasing expenditure on health in the domestic market and strong growth in generic sales in regulated markets are expected to sustain demand of pharma professionals in the future,” said Mr SudhanshuPandey, Joint Secretary, Department of Commerce, Ministry of Commerce and Industry, Government of India.
“Young pharmacy professionals in India can expect an increase in opportunities and jobs, which place an increased premium on skills in the near future as the industry experiences the next level of growth. The real task at hand is to sustain the predicted growth and incubate a strong educational structure that can produce world class pharmacy professionals,” said Ms Aparna Dutt Sharma, Chief Executive Officer, India Brand Equity Foundation (IBEF).
The skill base has served well to meet the niche demands for R&D skills and manufacturing infrastructure in the country so far. With the roadmap for future growth in place, the country should provide the gen next pharma professionals.
1. IBEF Pharmaceuticals Report – Page 7, para 1.
2. Article from Dr B Suresh, Principal, J.S.S. College of Pharmacy, Ootacamund – Para 1, line 7.
3. Article from Dr K G Revikumar, Principal, School of Pharmacy, Amrita Deemed University, Kochi, Kerala – Para 3, line 2.
4. International Current Pharmaceutical Journal – Page 3, para 3, line 18.
5. PwC Report: India Pharma Inc.: Capitalising on India’s Growth Potential – Page 15, para 2, line 3.
6. Planning Commission Working Groups Report – Page 4, para 2, line 4.
7. Indian Pharmaceutical Association – Page 3, para 2, line 5.
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke...
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA).
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance